https://www.selleckchem.com/pr....oducts/navoximod.htm
ollected during the original CrossCheck study showed that the identified features from our analysis were presented to clinicians during relapse events. Our proposed method predicted a higher rate of anomalies in patients with SSDs within the 30-day near relapse period and can be used to uncover individual-level behaviors that change before relapse. This approach will enable technologists and clinicians to build unobtrusive digital mental health tools that can predict incipient relapse in SSDs. Our proposed method predicted a higher ra
Like
Comment
Share
